BioSpecifics Technologies Corp (NASDAQ:BSTC) Downgraded by BidaskClub to “Sell”

BioSpecifics Technologies Corp (NASDAQ:BSTC) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Wednesday.

Separately, Zacks Investment Research upgraded shares of BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th.

Shares of BioSpecifics Technologies Corp (NASDAQ BSTC) traded up 1.069% during trading on Wednesday, reaching $48.766. 5,520 shares of the company were exchanged. BioSpecifics Technologies Corp has a 1-year low of $35.79 and a 1-year high of $58.79. The firm has a market capitalization of $349.70 million, a PE ratio of 29.918 and a beta of 1.76. The company’s 50-day moving average is $49.89 and its 200 day moving average is $52.12.

TRADEMARK VIOLATION WARNING: This article was posted by [[site]] and is the sole property of of [[site]]. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at [[permalink]].

A number of large investors have recently made changes to their positions in the stock. Bank of America Corp DE increased its stake in shares of BioSpecifics Technologies Corp by 122.6% in the first quarter. Bank of America Corp DE now owns 2,489 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 1,371 shares during the period. American International Group Inc. increased its stake in shares of BioSpecifics Technologies Corp by 7.1% in the first quarter. American International Group Inc. now owns 3,327 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 222 shares during the period. US Bancorp DE increased its stake in shares of BioSpecifics Technologies Corp by 1.1% in the second quarter. US Bancorp DE now owns 3,455 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 36 shares during the period. Public Employees Retirement System of Ohio increased its stake in shares of BioSpecifics Technologies Corp by 16.2% in the first quarter. Public Employees Retirement System of Ohio now owns 3,674 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 513 shares during the period. Finally, CAPROCK Group Inc. purchased a new stake in shares of BioSpecifics Technologies Corp during the second quarter valued at $206,000. Institutional investors own 55.12% of the company’s stock.

BioSpecifics Technologies Corp Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.